Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring early mechanistic data from a proteome study
(2018) In International Wound Journal 15(4). p.538-546- Abstract
Hypertrophic scars (HTS) and keloids are forms of aberrant cutaneous healing with excessive extracellular matrix (ECM) deposition. Current therapies still fall short and cause undesired effects. We aimed to thoroughly evaluate the ability of growth hormone releasing peptide 6 (GHRP6) to both prevent and reverse cutaneous fibrosis and to acquire the earliest proteome data supporting GHRP6's acute impact on aesthetic wound healing. Two independent sets of experiments addressing prevention and reversion effects were conducted on the classic HTS model in rabbits. In the prevention approach, the wounds were assigned to topically receive GHRP6, triamcinolone acetonide (TA), or vehicle (1% sodium carboxy methylcellulose [CMC]) from day 1 to... (More)
Hypertrophic scars (HTS) and keloids are forms of aberrant cutaneous healing with excessive extracellular matrix (ECM) deposition. Current therapies still fall short and cause undesired effects. We aimed to thoroughly evaluate the ability of growth hormone releasing peptide 6 (GHRP6) to both prevent and reverse cutaneous fibrosis and to acquire the earliest proteome data supporting GHRP6's acute impact on aesthetic wound healing. Two independent sets of experiments addressing prevention and reversion effects were conducted on the classic HTS model in rabbits. In the prevention approach, the wounds were assigned to topically receive GHRP6, triamcinolone acetonide (TA), or vehicle (1% sodium carboxy methylcellulose [CMC]) from day 1 to day 30 post-wounding. The reversion scheme was based on the infiltration of either GHRP6 or sterile saline in mature HTS for 4 consecutive weeks. The incidence and appearance of HTS were systematically monitored. The sub-epidermal fibrotic core area of HTS was ultrasonographically determined, and the scar elevation index was calculated on haematoxylin/eosin-stained, microscopic digitised images. Tissue samples were collected for proteomics after 1 hour of HTS induction and treatment with either GHRP6 or vehicle. GHRP6 prevented the onset of HTS without the untoward reactions induced by the first-line treatment triamcinolone acetonide (TA); however, it failed to significantly reverse mature HTS. The preliminary proteomic study suggests that the anti-fibrotic preventing effect exerted by GHRP6 depends on different pathways involved in lipid metabolism, cytoskeleton arrangements, epidermal cells' differentiation, and ECM dynamics. These results enlighten the potential success of GHRP6 as one of the incoming alternatives for HTS prevention.
(Less)
- author
- publishing date
- 2018-08
- type
- Contribution to journal
- publication status
- published
- subject
- in
- International Wound Journal
- volume
- 15
- issue
- 4
- pages
- 9 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:29464859
- scopus:85042179594
- ISSN
- 1742-481X
- DOI
- 10.1111/iwj.12895
- language
- English
- LU publication?
- no
- id
- a6bd52d1-a5ce-4a80-a505-599362595111
- date added to LUP
- 2018-12-13 15:31:07
- date last changed
- 2024-06-26 05:15:28
@article{a6bd52d1-a5ce-4a80-a505-599362595111,
abstract = {{<p>Hypertrophic scars (HTS) and keloids are forms of aberrant cutaneous healing with excessive extracellular matrix (ECM) deposition. Current therapies still fall short and cause undesired effects. We aimed to thoroughly evaluate the ability of growth hormone releasing peptide 6 (GHRP6) to both prevent and reverse cutaneous fibrosis and to acquire the earliest proteome data supporting GHRP6's acute impact on aesthetic wound healing. Two independent sets of experiments addressing prevention and reversion effects were conducted on the classic HTS model in rabbits. In the prevention approach, the wounds were assigned to topically receive GHRP6, triamcinolone acetonide (TA), or vehicle (1% sodium carboxy methylcellulose [CMC]) from day 1 to day 30 post-wounding. The reversion scheme was based on the infiltration of either GHRP6 or sterile saline in mature HTS for 4 consecutive weeks. The incidence and appearance of HTS were systematically monitored. The sub-epidermal fibrotic core area of HTS was ultrasonographically determined, and the scar elevation index was calculated on haematoxylin/eosin-stained, microscopic digitised images. Tissue samples were collected for proteomics after 1 hour of HTS induction and treatment with either GHRP6 or vehicle. GHRP6 prevented the onset of HTS without the untoward reactions induced by the first-line treatment triamcinolone acetonide (TA); however, it failed to significantly reverse mature HTS. The preliminary proteomic study suggests that the anti-fibrotic preventing effect exerted by GHRP6 depends on different pathways involved in lipid metabolism, cytoskeleton arrangements, epidermal cells' differentiation, and ECM dynamics. These results enlighten the potential success of GHRP6 as one of the incoming alternatives for HTS prevention.</p>}},
author = {{Fernández-Mayola, Maday and Betancourt, Lázaro and Molina-Kautzman, Alicia and Palomares, Sucel and Mendoza-Marí, Yssel and Ugarte-Moreno, Dayana and Aguilera-Barreto, Ana and Bermúdez-Álvarez, Yilian and Besada, Vladimir and González, Luis J and García-Ojalvo, Ariana and Mir-Benítez, Ana J and Urquiza-Rodríguez, Aleida and Berlanga-Acosta, Jorge}},
issn = {{1742-481X}},
language = {{eng}},
number = {{4}},
pages = {{538--546}},
publisher = {{Wiley-Blackwell}},
series = {{International Wound Journal}},
title = {{Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring early mechanistic data from a proteome study}},
url = {{http://dx.doi.org/10.1111/iwj.12895}},
doi = {{10.1111/iwj.12895}},
volume = {{15}},
year = {{2018}},
}